AstraZeneca Acquires Omniose; Financial Terms Not Disclosed
Benzinga Newsdesk 1 hour ago
M&A
Omniose, a preclinical biotechnology company, today announced that it has been acquired by AstraZeneca. The acquisition follows a productive three-year exclusive research collaboration with AstraZeneca.Under the terms
Omniose, a preclinical biotechnology company, today announced that it has been acquired by AstraZeneca. The acquisition follows a productive three-year exclusive research collaboration with AstraZeneca.
Under the terms of the agreement, Omniose has become a wholly owned subsidiary of AstraZeneca and a part of the Infectious Disease Unit. The acquisition brings Omniose’s proprietary bioconjugation platform and expertise into AstraZeneca, complementing existing capabilities and supporting its preclinical vaccine programs.